Stockreport

Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad population of myasthenia gravis patients [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+ and anti-LRP4+ BEERSE, BELGIUM, June 28, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag Internation [Read more]